Cargando…
Case series of sebelipase alfa hypersensitivity reactions and successful sebelipase alfa rapid desensitization
Allergic immune‐mediated hypersensitivity reactions are known potential complications of enzyme replacement therapy. Sebelipase alfa, recombinant lysosomal acid lipase (LAL), is a potentially life‐altering treatment for patients with LAL deficiency. There is very little information on the diagnosis...
Autores principales: | Huffaker, Michelle F., Liu, Anne Y., Enns, Gregory M., Vijay, Suresh, Amor, Antonio J., Adkinson, N. Franklin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718112/ https://www.ncbi.nlm.nih.gov/pubmed/31497479 http://dx.doi.org/10.1002/jmd2.12066 |
Ejemplares similares
-
Correction to: Case series of sebelipase alfa hypersensitivity reactions and successful sebelipase alfa rapid desensitization.
Publicado: (2020) -
Novel treatment options for lysosomal acid lipase deficiency: critical appraisal of sebelipase alfa
por: Su, Kim, et al.
Publicado: (2016) -
Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study
por: Jones, Simon A., et al.
Publicado: (2017) -
Sebelipase alfa enzyme replacement therapy in Wolman disease: a nationwide cohort with up to ten years of follow-up
por: Demaret, Tanguy, et al.
Publicado: (2021) -
Long-term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open-label studies
por: Vijay, Suresh, et al.
Publicado: (2021)